Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for rare and serious diseases. Its approved product, ZEVASKYN (prademagene zamikeracel), is an autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The company manufactures ZEVASKYN at its cGMP facility in Cleveland, Ohio, and distributes treatments through a network of qualified treatment centers. The development portfolio includes ABO-701, a PSMA-targeted synthetic immune receptor T cell (SIR-T) therapy for advanced prostate cancer, and adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases using novel AIM capsids. Abeona partners with academic researchers, patient advocacy organizations, and biotechnology companies to advance therapies for rare genetic diseases.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage abeonatherapeutics.com
Sector Healthcare IR page investors.abeonatherapeutics.com
Tags
cell and gene therapy, rare diseases, epidermolysis bullosa, prostate cancer, ophthalmic diseases, aav vectors, t cell therapy, ex vivo gene therapy, ZEVASKYN, prademagene zamikeracel, ABO-701, SIR-T, AIM Capsid Technology Platform, VIITAL
Press page investors.abeonatherapeutics.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 130.909M
Market cap (USD) $ 130.909M
P/E -2.10
PEG —
P/BV 1.04
P/S 22.49
P/OCF -2.06
P/FCF -1.97
Dividend yield —
Turnover / mcap —
Returns  
ROE 70.0%
ROI 39.7%
ROIC -49.8%
Profit margin 1,223.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 18.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 34
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 5.82M — 3.5M 1.414M 3M 10M — 2.998M 837K 889K 1.04M 925K 2.042M 4.404M 1.848M 481K — 291K — — — — 1.295M 1.147M — —
Net profit 71.183M -63.734M -54.188M -39.696M -84.936M -84.234M -76.282M -56.671M -27.319M -21.873M -14.526M -26.778M 4.449M -10.532M -2.532M -7.537M -17.34M -17.215M -21.744M -12.874M -1.7M -10.238M -6.935M -9.384M — —
Free cash flow -84.301M -58.461M -37.34M -43.613M -69.816M -36.355M -69.129M -48.354M -23.795M -13.533M -10.731M -1.611M -1K -3.968M -7.649M -6.867M -2.25M -6.588M 4.825M -1.961M -7.329M -8.632M -6.825M -8.998M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 5.27 5.57 5.01 3.08 0.34 1.57 3.27 7.14 15.85 4.85 3.36 — — — — — — — — — — — — — — —
Price performance 12m -0.05 0.11 0.63 8.14 -0.79 -0.52 -0.54 -0.55 2.27 0.44 — — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 124,000 107,000 81,000 — — 3M — — — 6.15M
↳ YoY growth +7.8% -13.7% -24.3%
↳ 5y CAGR -17.9% -33.8% +1.8% +89.1%
Borrowings, current (USD) — — — — — — — — 5.93M 12.2M
Borrowings, non-current (USD) — — — — — — — — 13M 7.81M
Lease liabilities (USD) — — 0.00 7.95M 6.97M 9.38M 7.63M 5.4M 4.09M 4.93M
Cash and deposits (USD) 69.1M 138M 18.8M 129M 12.6M 32.9M 14.2M 14.5M 23.4M 78.4M
Intangible assets (USD) 8.38M 3.98M 43M 36.2M 1.5M 1.38M 0.00 — — —
Right-of-use assets (USD) — — 8.9M 8.05M 7.03M 9.4M 5.33M 4.46M 3.55M 3.96M
Net debt (borrowings + leases - cash) (USD) — — — — — — — — -309,000 -53.5M
Cash flow detail
Operating cash flow (USD) -13M -22.9M -39.1M -62.8M -35M -65.7M -43.5M -37M -56M -76.3M
Purchases of property, plant and equipment (USD) -519,000 -860,000 -9.24M -6.31M -1.34M -4.15M -130,000 -331,000 -2.45M -7.98M
Purchases of intangible assets (USD) 0.00 0.00 -10.3M -199,000 — — — — — —
Change in receivables (cash effect) (USD) -9,000 17,000 26,000 81,000 — -3M 3M — — -6.15M
Change in inventories (cash effect) (USD) — — — — — — — — — -5.49M
Change in payables (cash effect) (USD) 2.82M -1.3M 7.67M — — 825,000 -5.49M 2.04M 1.51M 6.54M
Interest paid (cash effect) (USD) -6,000 -8,000 -11,000 — — — — — -2.67M -2.59M
Income taxes paid (cash effect) (USD) — — — — — — — -14,000 -7,000 —
Share-based compensation (USD) 4.83M 4.64M 8.18M 7.34M 5.85M 5.25M 3.05M 4.77M 6.63M 10.8M
Operating cash flow before change in receivables (USD) -13M -23M -39.1M -62.9M — -62.7M -46.5M — — -70.2M
Free cash flow (OCF - PPE - intangibles) (USD) -13.5M -23.8M -58.6M -69.3M -36.4M -69.8M -43.6M -37.3M -58.5M -84.3M
Income detail
Research and development expense (USD) 10.7M 17M 38.7M 48.6M 30.1M 34.3M 29M 31.1M 34.4M 26.8M
↳ 5y CAGR +20.5% +53.2% +112.9% +170.9% +44.9% +26.4% +11.3% -4.3% -6.7% -2.3%
Total comprehensive income (USD) — — — -76.3M -84.2M -85M -43.6M -54.1M -63.7M 71.3M
Comprehensive income to owners (USD) — — — -76.3M -84.2M -85M -43.6M -54.1M -63.7M 71.3M
Reported Mar 18, 2019 Mar 18, 2019 Aug 9, 2019 Mar 24, 2021 Mar 24, 2021 Mar 29, 2023 May 11, 2023 Mar 20, 2025 Mar 20, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 –

– 15 ZEVASKYN treatments completed since launch, including six during Q3 –

- QTC network expanded to eight sites; four centers have completed patient treatments –

- ZEVASKYN NTAP status became effective October 1, 2026 –

- $134.9 million in cash, cash equivalents and short-term investments as of September 30, 2026 –

- Separately announced acquisition of Phase 3-ready APT-1011 in eosinophilic esophagitis (EoE) and $30 million PIPE financing –

CLEVELAND, November 9, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported third-quarter 2026 financial results and provided an update on the commercial launch of ZEVASKYN.

“Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience,” said Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics.

- Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –

– ABO-801 acquired for $20 million equity consideration at closing with no upfront cash payment –

– Private placement financing includes leading life sciences investors –

CLEVELAND, November 9, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acquisition of APT-1011 (now ABO-801), a product candidate for eosinophilic esophagitis (EoE), from Ellodi Pharmaceuticals, and entered into a securities purchase agreement for a $30 million private placement financing. The acquisition, with no upfront cash consideration and the private placement financing, reflects Abeona’s disciplined approach to capital allocation.

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease,” said Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics.

November 02, 2026 7:46am EST

CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On October 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 5,100 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com .

ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.

Prompts

Abeona Therapeutics Inc. (ticker ABEO), listed in United States.

Company History

Date Change Detail
May 19, 2015 Renamed PLASMATECH BIOPHARMACEUTICALS INC → ABEONA THERAPEUTICS INC.
Sep 22, 2014 Renamed ACCESS PHARMACEUTICALS INC → PLASMATECH BIOPHARMACEUTICALS INC

ETFs Holding Abeona Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
FESM 0.01% 133,069 $ 822.366K Jun 30, 2026
AVSC 0.01% 76,271 $ 198.305K Nov 16, 2026
RESM 0.01% 59 $ 364.62 Jun 30, 2026
DFSU 0.00% 7,756 $ 17.761K Nov 12, 2026
DFAS 0.00% 36,849 $ 84.384K Nov 12, 2026
DFAC 0.00% 56,619 $ 129.658K Nov 12, 2026
DCOR 0.00% 14,102 $ 32.294K Nov 12, 2026